首页>
外国专利>
Terminal erythroid differentiation as a biomarker for prognosis and treatment, and therapeutic target in myeloid malignancies
Terminal erythroid differentiation as a biomarker for prognosis and treatment, and therapeutic target in myeloid malignancies
展开▼
机译:末端红细胞分化为预后和治疗的生物标志物,以及骨髓恶性肿瘤的治疗靶标
展开▼
页面导航
摘要
著录项
相似文献
摘要
The present invention relates to utilizing terminal erythroid differentiation (TED) as a biomarker for prognosis and as a therapeutic target in myeloid malignancies, in particular myelodyplastic syndromes. The present invention relates to identifying patients with myelodysplastic syndromes at risk for poor survival/outcomes who would benefit from aggressive treatment, by characterizing their TED profile using protein and gene expression markers and combinations thereof.
展开▼